Search
avacopan
Indications:
- ANCA-associated vasculitis
- adjunctive therapy to cyclophosphamide or rituximab*
* non-inferior to prednisone as adjunctive therapy
Dosage:
- 30 mg PO BID for 52 weeks
Adverse effects:
- infections, including opportunistic infections*
* prophylactic therapy for Pneumocystis jirovecii indicated
Mechanism of action:
- C5a receptor (CD88) inhibitor
General
receptor antagonist
anti-inflammatory agent
Database Correlations
PUBCHEM cid=49841217
References
- Jayne DRW, Merkel PA, Schall TJ, Bekker P for the ADVOCATE Study
Avacopan for the Treatment of ANCA-Associated Vasculitis
N Engl J Med 2021; 384:599-609. Feb 18
PMID: 33596356
https://www.nejm.org/doi/full/10.1056/NEJMoa2023386